| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $120,560 | 7 | 100 |
Sells | $0 | 0 | 0 |
| GARCIA RUBEN A | General Counsel | 2 | $60,656 | 0 | $0 | $60,656 |
| Davis Jason | Chief Financial Officer | 1 | $28,973 | 0 | $0 | $28,973 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER | 3 | $19,531 | 0 | $0 | $19,531 |
| Khoja Hamid | Chief Scientific Officer | 1 | $11,400 | 0 | $0 | $11,400 |
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to …
Over the last 12 months, insiders at FibroBiologics, Inc. Common Stock have bought $120,560 and sold $0 worth of FibroBiologics, Inc. Common Stock stock.
On average, over the past 5 years, insiders at FibroBiologics, Inc. Common Stock have bought $68,680 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: GARCIA RUBEN A (General Counsel) — $60,656. Davis Jason (Chief Financial Officer) — $28,973. O'HEERON PETE (CHIEF EXECUTIVE OFFICER) — $19,531.
The last purchase of 15,872 shares for transaction amount of $6,006 was made by O'HEERON PETE (CHIEF EXECUTIVE OFFICER) on 2026‑03‑04.
| 2026-03-04 | O'HEERON PETE | CHIEF EXECUTIVE OFFICER | 15,872 0.0381% | $0.38 | $6,006 | -84.95% | ||
| 2026-03-04 | Khoja Hamid | Chief Scientific Officer | 30,000 0.0724% | $0.38 | $11,400 | -84.95% | ||
| 2026-03-03 | O'HEERON PETE | CHIEF EXECUTIVE OFFICER | 18,200 0.0419% | $0.41 | $7,373 | -85.48% | ||
| 2026-03-02 | O'HEERON PETE | CHIEF EXECUTIVE OFFICER | 17,428 0.0447% | $0.35 | $6,152 | -86.53% | ||
| 2026-03-02 | Davis Jason | Chief Financial Officer | 70,000 0.2103% | $0.41 | $28,973 | -86.53% | ||
| 2026-02-27 | GARCIA RUBEN A | General Counsel | 40,000 0.0948% | $0.33 | $13,056 | -82.72% | ||
| 2025-12-11 | GARCIA RUBEN A | General Counsel | 140,000 0.3868% | $0.34 | $47,600 | -80.43% | ||
| 2025-05-27 | Khoja Hamid | Chief Scientific Officer | 20,000 0.1365% | $0.84 | $16,800 | -55.91% |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER | 5958147 89.4859% | $5.9M | 3 | 0 | |
| GARCIA RUBEN A | General Counsel | 180000 2.7034% | $178,200.00 | 2 | 0 | |
| Davis Jason | Chief Financial Officer | 70000 1.0513% | $69,300.00 | 1 | 0 | |
| Khoja Hamid | Chief Scientific Officer | 61250 0.9199% | $60,637.50 | 2 | 0 | <0.0001% |
$13,664,154 | 40 | -70.35% | $7.05M | |
$29,645,465 | 28 | 8.09% | $6.48M | |
$63,749,694 | 24 | -12.24% | $6.4M | |
$287,718 | 15 | -41.45% | $5.68M | |
$1,246,170 | 12 | 65.67% | $5.42M |
| Increased Positions | 14 | +19.18% | 726,477 | +13.42% |
| Decreased Positions | 24 | -32.88% | 2M | -31.79% |
| New Positions | 6 | New | 375,466 | New |
| Sold Out Positions | 17 | Sold Out | 1M | Sold Out |
| Total Postitions | 63 | -13.7% | 4M | -18.37% |